Background: MK is a novel cytokine, which is pathologically

implicated in a number of inflammatory disease processes including kidney disease. It has potential as both a biomarker and a biological therapeutic target in acute and CKD. To date there is little data on MK levels in humans with CKD. Method: This is a prospective, observational study. Plasma, serum and urine samples were simultaneously obtained from CKD outpatients and healthy I-BET-762 volunteers (HV), stored at −70°C, and assayed for MK levels using a commercially available MK-ELISA kit (Cellmid Ltd, Sydney, Australia). MK levels were compared between 2 severity groups, divided as HV and stage 1–2, compared with a second group of stage 3–5. Result: Samples were obtained from 20 HV and 126 CKD patients. Serum MK levels were significantly higher in the CKD stage 3–5 group than the HV or CKD 1–2 group (3009 (SD = 1942) vs 870 pg/mL (SD = 384) P < 0.001). Urine MK levels were significantly higher in the CKD stage 3–5 group than the HV or CKD 1–2 group (6008 (SD = 13462) vs 654 pg/mL (SD = 1517) P ≤ 0.001). Conclusion: Serum and urine Midkine levels are elevated in stage 3–5 CKD patients compared to non-CKD or lesser stages 1–2. Whether this is association, or reflecting

part of the pathological process Afatinib order requires further exploration. 161 MIDKINE LEVELS CAN BE MEASURED IN EITHER PLASMA OR SERUM V CAMPBELL1,2,3, NA GRAY1,3, C ANSTEY2,3, R GATELY1, C CLARK1,2, E NOBLE1, K MAHADEVAN1,2, PR HOLLETT1,2, A POLLOCK1, D JONES4, S HALL5 1Renal Unit, Nambour General Hospital, Nambour, Queensland; 2Sunshine Coast Clinical School, The University of Queensland, Nambour, Queensland; 3Intensive Care Unit, Nambour General hospital, Nambour, Queensland, Australia; 4Cellmid Ltd; 5Pathology North – Hunter New England Aim: To compare Midkine tuclazepam (MK) levels when measured in plasma and serum. Background: Midkine is a novel cytokine, which is pathologically implicated in a number of inflammatory and malignant disease processes. Levels have usually been measured in serum, however protein assays can be performed on either plasma or serum. Because of the increasing number of both

serum and plasma banks being stored as part of large clinical trials, validating the assay in both sample types would allow further investigation of this cytokine. Methods: Plasma and serum samples were simultaneously obtained from chronic kidney disease (CKD) outpatients and healthy volunteers (HV), stored at −70°C, and assayed for MK levels using a commercially available MK-ELISA kit (Cellmid Ltd, Sydney, Australia). Data were analysed using multivariate linear regression. Results: Samples were obtained from 20 HV and 126 CKD patients. The causes of CKD included 26% diabetes, 37% hypertension/vascular, 9% glomerulonephritis, 5% polycystic disease, and 24% other. The CKD stages ranged from 1–5, with the majority being stage 3–4.